<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00376168</url>
  </required_header>
  <id_info>
    <org_study_id>PB-06-001</org_study_id>
    <nct_id>NCT00376168</nct_id>
  </id_info>
  <brief_title>A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease</brief_title>
  <official_title>A Phase III, Multicenter, Randomized, Double-Blind Trial to Assess the Safety and Efficacy of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients With Gaucher Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protalix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protalix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gaucher disease, the most prevalent lysosomal storage disorder, is caused by mutations in the
      human glucocerebrosidase gene (GCD) leading to reduced activity of the lysosomal enzyme
      glucocerebrosidase and thereby to the accumulation of substrate glucocerebroside (GlcCer) in
      the cells of the monocyte-macrophage system.

      This is the second trial to utilize a recombinant active form of lysosomal enzyme,
      glucocerebrosidase, (human prGCD) which is expressed and purified in a bioreactor system from
      transformed carrot plant root cell line.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a multi-center, randomized, double-blind, parallel group, dose-ranging trial to
      assess the safety and efficacy of prGCD in 30 untreated patients with Gaucher disease.
      Patients will receive IV infusion of prGCD every two weeks at the selected medical center.
      The duration of the study will be nine months. At the end of the 9-month treatment period (20
      visits, 38 weeks) eligible patients will be offered enrollment in an open-label extension
      study.

      There will be two treatment groups, 15 patients in each treatment group.

      Treatment Group I: 30 units/kg every 2 weeks. Treatment Group II: 60 units/kg every 2 weeks.

      All patients will have pharmacokinetic data collected over approximately 3 hours with
      frequent blood samples following the first and final doses of prGCD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Spleen Volume Measured by MRI.</measure>
    <time_frame>Baseline and 9 months</time_frame>
    <description>Calculated as percent change in spleen volume from Baseline to 9 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Liver Volume</measure>
    <time_frame>Baseline and 9 months</time_frame>
    <description>Calculated as percent change in liver volume from Baseline to 9 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin</measure>
    <time_frame>Baseline and Month 9</time_frame>
    <description>Absolute change in Hemoglobin concentration from Baseline to Month 9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Platelet Count</measure>
    <time_frame>Baseline and Month 9</time_frame>
    <description>Change in Platelet count from Baseline to Month 9</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Chitotriosidase</measure>
    <time_frame>Baseline and Month 9</time_frame>
    <description>Change in Chitotriosidase from Baseline to Month 9</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Gaucher Disease</condition>
  <arm_group>
    <arm_group_label>prGCD 30 Units/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>prGCD 60 Units/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plant cell expressed recombinant glucocerebrosidase (prGCD)</intervention_name>
    <description>Intravenous infusion every two weeks for 9 months</description>
    <arm_group_label>prGCD 30 Units/kg</arm_group_label>
    <other_name>Taliglucerase alfa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plant cell expressed recombinant glucocerebrosidase (prGCD)</intervention_name>
    <description>Intravenous infusion every 2 weeks for 9 months</description>
    <arm_group_label>prGCD 60 Units/kg</arm_group_label>
    <other_name>Taliglucerase alfa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females, 18 years or older

          -  Confirmed enzymatic diagnosis of Gaucher disease

          -  Splenomegaly defined as greater than eight times the expected volume (measured volume
             divided by estimated volume (0.2% of body weight)] as determined by MRI volumetric
             analysis

          -  Female patients of child-bearing potential who agree to use a medically acceptable
             method of contraception

          -  Thrombocytopenia (defined as platelet counts below the lower limit of normal) and/or
             anemia (defined by hemoglobin level at least 1 g/dL below normal range according to
             sex and age).

          -  Patients who have not received ERT in the past or patients whoc have not received ERT
             in the past 12 months and have a negative anti-glucocerebrosidase antibody test.

          -  Patients who have not received substrate reduction therapy (SRT) in the past 12
             months.

          -  Ability to provide a written informed consent.

        Exclusion Criteria:

          -  Currently taking another experimental drug for any condition

          -  Pregnant or nursing

          -  Presence of HIV and/or, HBsAg and/or hepatitis C infections

          -  Presence of severe neurological signs and symptoms, defined as complete ocular
             paralysis, overt myoclonus or history of seizures, characteristic of neuronopathic
             Gaucher disease.

          -  Previous anaphylactoid reaction to Cerezyme® or Ceredase®.

          -  History of allergy to carrots.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ari Zimran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaare Zedek Medical Center, Jerusalem, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Research Foundation for Lysosomal Storage Diseases</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Medical Genetics, Emory University School of Medicine</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pontificia Universidad Catolica de Chile</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita &quot;La Sapienza&quot;</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morningside Medi-Clinic</name>
      <address>
        <city>Morningside</city>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Chile</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2006</study_first_submitted>
  <study_first_submitted_qc>September 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2006</study_first_posted>
  <results_first_submitted>May 11, 2012</results_first_submitted>
  <results_first_submitted_qc>July 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 26, 2012</results_first_posted>
  <last_update_submitted>July 25, 2012</last_update_submitted>
  <last_update_submitted_qc>July 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ELELYSO 30 Units/kg</title>
          <description>Taliglucerase alfa 30 Units/kg by intravenous infusion every two weeks</description>
        </group>
        <group group_id="P2">
          <title>ELELYSO 60 Units/kg</title>
          <description>Taliglucerase alfa 60 Units/kg by intravenous infusion every two weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16">One patient randomized but not treated</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ELELYSO 30 Units/kg</title>
          <description>Taliglucerase alfa 30 Units/kg by intravenous infusion every two weeks</description>
        </group>
        <group group_id="B2">
          <title>ELELYSO 60 Units/kg</title>
          <description>Taliglucerase alfa 60 Units/kg by intravenous infusion every two weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.3" spread="11.8"/>
                    <measurement group_id="B2" value="36.0" spread="12.2"/>
                    <measurement group_id="B3" value="36.2" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Spleen Volume</title>
          <description>Measured by MRI</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2130.94" spread="1154.72"/>
                    <measurement group_id="B2" value="2117.38" spread="1356.17"/>
                    <measurement group_id="B3" value="2120" spread="1200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Liver Volume</title>
          <description>Measured by MRI</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2880.60" spread="736.12"/>
                    <measurement group_id="B2" value="2481.31" spread="452.74"/>
                    <measurement group_id="B3" value="2600" spread="600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin</title>
          <description>Measured in central laboratory</description>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.2" spread="1.7"/>
                    <measurement group_id="B2" value="11.4" spread="2.6"/>
                    <measurement group_id="B3" value="12" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Platelet Count</title>
          <description>Measured in local laboratory</description>
          <units>count/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75,320" spread="40,861"/>
                    <measurement group_id="B2" value="65,038" spread="28,668"/>
                    <measurement group_id="B3" value="70,000" spread="32,000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chitotriosidase</title>
          <description>Gaucher disease biomarker</description>
          <units>nmol/ml/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28158" spread="11686"/>
                    <measurement group_id="B2" value="24702" spread="17428"/>
                    <measurement group_id="B3" value="26000" spread="14000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Spleen Volume Measured by MRI.</title>
        <description>Calculated as percent change in spleen volume from Baseline to 9 months</description>
        <time_frame>Baseline and 9 months</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>ELELYSO 30 Units/kg</title>
            <description>Taliglucerase alfa 30 Units/kg by intravenous infusion every two weeks</description>
          </group>
          <group group_id="O2">
            <title>ELELYSO 60 Units/kg</title>
            <description>Taliglucerase alfa 60 Units/kg by intravenous infusion every two weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Spleen Volume Measured by MRI.</title>
          <description>Calculated as percent change in spleen volume from Baseline to 9 months</description>
          <population>Intent to treat</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.91" spread="7.79"/>
                    <measurement group_id="O2" value="-38.01" spread="9.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The primary efficacy analysis was based on two one-sample t-tests (one for each treatment group) to determine if the percent change in spleen volume is different than zero.
With 12 patients in each treatment group, there was greater than 95% power to detect a change of 20% or more using a one-sample t-test (alpha=0.025, 2-sided test to allow for each group to be tested separately) to evaluate the primary outcome of percent change in spleen volume after nine months.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>one-sample t-test</method>
            <method_desc>one-sample t-test (combined) to test the null hypothesis that percent change = 0</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary efficacy analysis was based on two one-sample t-tests (one for each treatment group) to determine if the percent change in spleen volume is different than zero.
With 12 patients in each treatment group, there was greater than 95% power to detect a change of 20% or more using a one-sample t-test (alpha=0.025, 2-sided test to allow for each group to be tested separately) to evaluate the primary outcome of percent change in spleen volume after nine months.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>threshold for statistical significance = 0.025</p_value_desc>
            <method>one-sample t-test</method>
            <method_desc>one-sample t-test (combined) to test the null hypothesis that percent change = 0</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Liver Volume</title>
        <description>Calculated as percent change in liver volume from Baseline to 9 months</description>
        <time_frame>Baseline and 9 months</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>ELELYSO 30 Units/kg</title>
            <description>Taliglucerase alfa 30 Units/kg by intravenous infusion every two weeks</description>
          </group>
          <group group_id="O2">
            <title>ELELYSO 60 Units/kg</title>
            <description>Taliglucerase alfa 60 Units/kg by intravenous infusion every two weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Liver Volume</title>
          <description>Calculated as percent change in liver volume from Baseline to 9 months</description>
          <population>Intent to treat</population>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.48" spread="11.27"/>
                    <measurement group_id="O2" value="-11.11" spread="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>For each of the secondary endpoints, a one-sample t-test (% change in liver volume, mean change in hemoglobin and platelet count) was examined first for each dose using the step-down approach. Next, a mixed effects model that included dose and time, with subject as a random effect, was fit to examine whether there was a difference between dose groups, for those outcomes that were tested in the step-down approach.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0041</p_value>
            <method>One-sample t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For each of the secondary endpoints, a one-sample t-test (% change in liver volume, mean change in hemoglobin and platelet count) was examined first for each dose using the step-down approach. Next, a mixed effects model that included dose and time, with subject as a random effect, was fit to examine whether there was a difference between dose groups, for those outcomes that were tested in the step-down approach.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>One-sample t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin</title>
        <description>Absolute change in Hemoglobin concentration from Baseline to Month 9</description>
        <time_frame>Baseline and Month 9</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>ELELYSO 30 Units/kg</title>
            <description>Taliglucerase alfa 30 Units/kg by intravenous infusion every two weeks</description>
          </group>
          <group group_id="O2">
            <title>ELELYSO 60 Units/kg</title>
            <description>Taliglucerase alfa 60 Units/kg by intravenous infusion every two weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin</title>
          <description>Absolute change in Hemoglobin concentration from Baseline to Month 9</description>
          <population>Intent to treat</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.4"/>
                    <measurement group_id="O2" value="2.2" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>For each of the secondary endpoints, a one-sample t-test (% change in liver volume, mean change in hemoglobin and platelet count) was examined first for each dose using the step-down approach. Next, a mixed effects model that included dose and time, with subject as a random effect, was fit to examine whether there was a difference between dose groups, for those outcomes that were tested in the step-down approach.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <method>One-sample t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For each of the secondary endpoints, a one-sample t-test (% change in liver volume, mean change in hemoglobin and platelet count) was examined first for each dose using the step-down approach. Next, a mixed effects model that included dose and time, with subject as a random effect, was fit to examine whether there was a difference between dose groups, for those outcomes that were tested in the step-down approach.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>One-sample t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Platelet Count</title>
        <description>Change in Platelet count from Baseline to Month 9</description>
        <time_frame>Baseline and Month 9</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>ELELYSO 30 Units/kg</title>
            <description>Taliglucerase alfa 30 Units/kg by intravenous infusion every two weeks</description>
          </group>
          <group group_id="O2">
            <title>ELELYSO 60 Units/kg</title>
            <description>Taliglucerase alfa 60 Units/kg by intravenous infusion every two weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Platelet Count</title>
          <description>Change in Platelet count from Baseline to Month 9</description>
          <population>Intent to treat</population>
          <units>count/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11,427" spread="20,214"/>
                    <measurement group_id="O2" value="41,494" spread="47,063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>For each of the secondary endpoints, a one-sample t-test (% change in liver volume, mean change in hemoglobin and platelet count) was examined first for each dose using the step-down approach. Next, a mixed effects model that included dose and time, with subject as a random effect, was fit to examine whether there was a difference between dose groups, for those outcomes that were tested in the step-down approach.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0460</p_value>
            <method>One-sample t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For each of the secondary endpoints, a one-sample t-test (% change in liver volume, mean change in hemoglobin and platelet count) was examined first for each dose using the step-down approach. Next, a mixed effects model that included dose and time, with subject as a random effect, was fit to examine whether there was a difference between dose groups, for those outcomes that were tested in the step-down approach.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0031</p_value>
            <method>One-sample t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Chitotriosidase</title>
        <description>Change in Chitotriosidase from Baseline to Month 9</description>
        <time_frame>Baseline and Month 9</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>ELELYSO 30 Units/kg</title>
            <description>Taliglucerase alfa 30 Units/kg by intravenous infusion every two weeks</description>
          </group>
          <group group_id="O2">
            <title>ELELYSO 60 Units/kg</title>
            <description>Taliglucerase alfa 60 Units/kg by intravenous infusion every two weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Chitotriosidase</title>
          <description>Change in Chitotriosidase from Baseline to Month 9</description>
          <population>Intent to treat</population>
          <units>nmol/ml/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14,548" spread="8,025.8"/>
                    <measurement group_id="O2" value="-12,538" spread="14,489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ELELYSO 30 Units/kg</title>
          <description>Taliglucerase alfa 30 Units/kg by intravenous infusion every two weeks</description>
        </group>
        <group group_id="E2">
          <title>ELELYSO 60 Units/kg</title>
          <description>Taliglucerase alfa 60 Units/kg by intravenous infusion every two weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Glycosuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Einat Almon</name_or_title>
      <organization>Protalix Ltd.</organization>
      <phone>972-4-9889488 ext 137</phone>
      <email>einata@protalix.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

